Third Party CMV Viral Specific T-Cells for Refractory CMV Viremia and Disease after Hematopoietic Transplant

In Phase I/II trials, scientists treated 67 subjects for CMV viremia or disease arising after allogeneic hematopoietic cell transplant with adoptive transfer of banked off-the-shelf, 3rd party, CMVpp65-sensitized T cells.